Trial Profile

A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SEL 212 (Primary) ; Pegadricase; Sirolimus
Indications Gout; Hyperuricaemia
Focus Adverse reactions
Sponsors Selecta Biosciences

Most Recent Events

17 Jun 2017 Results assessing initial safety and impact on serum uric acid levels and anti-drug antibodies presented at the 18th Annual Congress of the European League Against Rheumatism.
06 Jun 2017 Data from this trial will be presented at the Annual European Congress of Rheumatology (EULAR 2017), according to a Selecta Biosciences media release.
26 Jan 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com